CONTRACT_GRANT_ID	CATEGORY	DESCRIPTION	END_DATE	EXTERNAL_ID	LINK	NAME	PROGRAM_ID	START_DATE
4247	NIH	This is a Phase IV, investigator-initiated, partially blinded, randomized, multi-center clinical trial designed to evaluate the mechanistic effects of TNF-&#945; inhibition on clinical and mechanistic measures in RA patients. Subjects will be randomized to one of two active treatment arms, etanercept or adalimumab, and will receive treatment using standard dosing regimens for 24 weeks. Subjects will be randomized in a 2:1 ratio until 40 and 20 subjects are treated with etanercept and adalimumab, respectively.	2015-07-31 00:00:00	AI078907	https://projectreporter.nih.gov/project_info_description.cfm?aid=7902713&icde=29752450 https://clinicaltrials.gov/ct2/show/NCT00837434	Anti-TNF Agents in RA (ARA06)	39	2010-08-01 00:00:00
